DRMA

Dermata Therapeutics, Inc.

$0.71

-7.21%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Source: Yahoo Finance
AI summary

Price & performance

1M-19.5%
3M-30.0%
YTD-58.3%
1Y-78.9%
52-week range—
Beta0.18
Full chart and returns against a benchmark

Q-Score

20/ 100

Quality against peers; 50 is the peer median.

Growth15
Risk31
Performance21
Valuation25
Profitability—
Leverage51
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$7.6M
Net margin—
Historical fundamentals

Red flags in filings

2active red flags
Going-concern doubtMar 26, 2026
Auditor changeFeb 3, 2026
Filings, findings and the timeline

Valuation

DRMAIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B1.026.22PEG—4.02
Dividend yield0.00%
Every valuation metric